Greenwich LifeSciences, Inc.
GLSI
$9.86
-$0.13-1.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.93M | 437.00K | 353.50K | 342.70K | 503.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.08M | 2.73M | 2.66M | 2.54M | 2.84M |
| Operating Income | -8.08M | -2.73M | -2.66M | -2.54M | -2.84M |
| Income Before Tax | -8.04M | -2.67M | -2.61M | -2.47M | -2.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.04M | -2.67M | -2.61M | -2.47M | -2.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.04M | -2.67M | -2.61M | -2.47M | -2.75M |
| EBIT | -8.08M | -2.73M | -2.66M | -2.54M | -2.84M |
| EBITDA | -8.08M | -2.73M | -2.66M | -2.54M | -2.84M |
| EPS Basic | -0.61 | -0.20 | -0.20 | -0.19 | -0.21 |
| Normalized Basic EPS | -0.38 | -0.13 | -0.13 | -0.12 | -0.13 |
| EPS Diluted | -0.61 | -0.20 | -0.20 | -0.19 | -0.21 |
| Normalized Diluted EPS | -0.38 | -0.13 | -0.13 | -0.12 | -0.13 |
| Average Basic Shares Outstanding | 13.15M | 13.14M | 12.91M | 12.86M | 12.85M |
| Average Diluted Shares Outstanding | 13.15M | 13.14M | 12.91M | 12.86M | 12.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |